Foundation For The National Institutes Of Health, Inc.
Foundation For The National Institutes Of Health, Inc.
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Foundation For The National Institutes Of Health, Inc.? Learn more here.
About this organization
Mission
The Foundation for the National Institutes of Health creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives.
About
SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS -INVESTIGATING NEW TREATMENTS FOR LUNG CANCER PATIENTSSHORTNESS OF BREATH. EXHAUSTION. LOSS OF APPETITE. THESE ARE JUST SOME OF THE SYMPTOMS EXPERIENCED BY PATIENTS WITH LUNG AND BRONCHIAL CANCER, WHICH REMAINS THE SECOND MOST COMMON CANCER DIAGNOSIS IN THE UNITED STATES ACCORDING TO THE NATIONAL CANCER INSTITUTE (NCI). ABOUT 85 PERCENT OF THOSE DIAGNOSED HAVE NON-SMALL CELL LUNG CANCER, A DISEASE IN WHICH CANCER CELLS FORM IN THE TISSUES OF THE LUNG.IN 2018, THE FNIH, NCI AND PARTNERS PREPARED FOR A MAJOR EXPANSION OF THE LUNG CANCER MASTER PROTOCOL (LUNG-MAP) CLINICAL TRIAL. THE TRIAL PREVIOUSLY TESTED TREATMENTS FOR PEOPLE WITH ADVANCED STAGE SQUAMOUS CELL LUNG CANCER. IT IS NOW OPEN TO PATIENTS WITH ALL TYPES OF ADVANCED STAGE NON-SMALL CELL LUNG CANCER. THIS DEVELOPMENT WILL ENABLE THOUSANDS OF NEW PATIENTS TO ENROLL IN LUNG-MAP, JOINING THE MORE THAN 1,800 PATIENTS, LIKE ANNIE BURKE, ALREADY PARTICIPATING AT 640 U.S. MEDICAL CENTERS AND COMMUNITY HOSPITALS ACROSS THE COUNTRY.LAUNCHED IN 2014, LUNG-MAP IS THE FIRST MAJOR NCI CANCER TRIAL TO TEST MULTIPLE CANCER TREATMENTS SIMULTANEOUSLY UNDER ONE "UMBRELLA" DESIGN. THIS PIONEERING RESEARCH MODEL IS MORE FLEXIBLE AND FASTER THAN TRADITIONAL CLINICAL TRIALS AS IT ENABLES RESEARCHERS TO SHARE ONE TRIAL STRUCTURE AND RECRUITMENT PROCESS. PATIENTS ARE TESTED ONCE FOR MORE THAN 200 CANCER-RELATED GENETIC ALTERATIONS BEFORE THEY ARE ASSIGNED TO INVESTIGATIONAL TREATMENT STUDIES BASED ON THEIR UNIQUE TUMOR PROFILE. PATIENTS WITHOUT A MATCHING GENETIC ALTERATION FOR A CORRESPONDING THERAPY WITHIN LUNG-MAP ARE PLACED ON AN IMMUNOTHERAPY REGIME."A GREAT THING ABOUT THE LUNG-MAP DESIGN IS THAT THE PATIENTS CAN MOVE FROM ONE STUDY TO THE NEXT TO THE NEXT," SAID JESSICA JORDAN, RESEARCH COORDINATOR, VA CONNECTICUT HEALTHCARE SYSTEMS. "EVERY SINGLE STUDY THESE DAYS REQUIRES TISSUE. WE ONLY HAVE TO SUBMIT ONE BLOCK OF TISSUE AND A PATIENT IS POTENTIALLY ABLE TO RECEIVE MORE THAN ONE LINE OF TREATMENT ON THE TRIAL IF THEIR GENERAL HEALTH ALLOWS. THAT'S THE MAJOR BENEFIT."THE TRIAL HAS ALREADY COMPLETED SEVEN OUT OF 10 LAUNCHED STUDIES, WITH TWO MORE SUB-STUDIES SCHEDULED TO OPEN IN 2019, OFFERING PATIENTS A PERSONALIZED APPROACH TO FINDING THE INVESTIGATIONAL DRUGS THAT WILL FIGHT THEIR CANCER. IMPROVE DIAGNOSIS OF KIDNEY INJURYIN 2018, THE FNIH BIOMARKERS CONSORTIUM ACHIEVED AN UNPRECEDENTED MILESTONE BY RECEIVING THE FIRST EVER QUALIFICATION OF A CLINICAL SAFETY BIOLOGICAL MARKER (BIOMARKER) AWARDED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). THE QUALIFICATION APPLIES TO A COMPOSITE MEASURE OF SIX URINE BIOMARKERS THAT RELIABLY CHANGE IN RESPONSE TO DRUG-INDUCED KIDNEY INJURY PRIOR TO IRREVERSIBLE DAMAGE AND EARLIER THAN TRADITIONAL BIOMARKERS. THIS SET OF BIOMARKERS CAN NOW BE USED TO AID IN THE DETECTION OF ACUTE KIDNEY INJURY IN HEALTHY VOLUNTEERS DURING EARLY PHASE CLINICAL TRIALS. IT WILL HELP IMPROVE THE DEVELOPMENT OF SAFE AND EFFECTIVE MEDICINES FOR PATIENTS WHERE CONCERN HAS BEEN RAISED THAT AN INVESTIGATIONAL DRUG MAY CAUSE KIDNEY INJURY.THIS MAJOR MILESTONE WAS MADE POSSIBLE BY THE RELENTLESS EFFORTS OF GOVERNMENT, NOT-FOR-PROFIT AND INDUSTRY PARTNERS SHARING INTELLECTUAL AND FINANCIAL RESOURCES TO FAST-TRACK THE DEVELOPMENT OF THESE CRITICAL BIOMARKERS. THE PATHWAY SET FORTH BY THE TEAM MAY HELP OTHERS SUBMITTING BIOMARKERS FOR QUALIFICATION BY THE FDA, EXPLAINED STEFAN SULTANA, M.D.,: "THE CUTTING-EDGE IS A LONELY PLACE TO BE BECAUSE NO ONE HAS BEEN DOWN THIS PATH BEFORE, SO WE'RE DEVELOPING NEW SCIENCE AND NEW WAYS OF DOING THINGS WITH THE REGULATORY AGENCIES. HOPEFULLY THE LESSONS WE LEARNED MAKE IT A LOT EASIER FOR OTHER GROUPS TO PURSUE QUALIFICATION OF SAFETY BIOMARKERS."TRACKING KNEE OSTEOARTHRITISMILLIONS OF PEOPLE WORLDWIDE WILL EXPERIENCE OSTEOARTHRITIS AS THEY AGE, AS IT IS THE MOST COMMON DISORDER OF THE JOINTS AND A MAJOR CAUSE OF DISABILITY IN OLDER ADULTS. DESPITE ITS PREVALENCE, THERE REMAINS A LACK OF TOOLS TO ACCURATELY EVALUATE PATIENTS, WHICH MAKES IT DIFFICULT TO DEVELOP NEW TREATMENTS.IN 2018, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED A NEW PROJECT THAT WILL HELP PHYSICIANS AND PATIENTS, LIKE CINDY COPENHAVER, BETTER UNDERSTAND KNEE OSTEOARTHRITIS. RESEARCHERS WILL SEEK REGULATORY QUALIFICATION OF A NEW SET OF IMAGING (I.E., MRI) AND BIOCHEMICAL (I.E., URINE, SERUM) BIOMARKERS THAT PREDICT STRUCTURAL CHANGES IN THE JOINT CAUSED BY KNEE OSTEOARTHRITIS OVER TIME. THE FNIH IDENTIFIED THESE BIOMARKERS THROUGH A PREVIOUS PROJECT AND SHOWED THAT THEY MORE PRECISELY PREDICT AND MONITOR CHANGES IN THE KNEE COMPARED TO THE CURRENT STANDARD THAT USES X-RAY IMAGES. THE ACCEPTANCE OF THESE BIOMARKERS FOR THE DEVELOPMENT OF NEW DRUGS WILL PAVE THE WAY FOR IMPROVED TREATMENT OPTIONS FOR OSTEOARTHRITIS PATIENTS.SHAPING PERSONALIZED CANCER THERAPIESNEARLY EVERYONE HAS A FAMILY MEMBER OR FRIEND AFFECTED BY CANCER. FORTUNATELY, RECENT ADVANCES IN IMMUNOTHERAPIES HAVE SHOWN PROMISING RESPONSES IN CERTAIN CANCER TYPES. WHAT RESEARCHERS STILL NEED TO UNCOVER IS HOW AND WHEN TO BEST PAIR AN IMMUNOTHERAPY TO A SPECIFIC PATIENT.IN 2018, THE FNIH, NIH, FDA AND 12 PHARMACEUTICAL COMPANIES CONTINUED THEIR WORK TO BETTER UNDERSTAND HOW IMMUNOTHERAPIES ARE EFFECTIVE IN SOME PATIENTS AND TO ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS THROUGH THE PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT). LEVERAGING THEIR COLLECTIVE EXPERTISE, CAPABILITIES AND RESOURCES, THE PARTNERS SET OUT TO IDENTIFY AND DEVELOP ROBUST, STANDARDIZED BIOMARKERS AND TESTS THAT WILL SUPPORT THE SELECTION AND CLINICAL TESTING OF IMMUNE-ONCOLOGY AND COMBINATION THERAPIES FOR PATIENTS. THESE BIOMARKERS AND TESTS WILL BE SHARED WITH THE BROADER RESEARCH COMMUNITY SO THAT THEY CAN BE USED EFFECTIVELY IN CLINICAL TRIALS CONDUCTED ANYWHERE IN THE CANCER FIELD."THE PACT TEAM HAS WORKED ACROSS BARRIERS TO BRING DIFFERENT PEOPLE TOGETHER TO DO SOMETHING THAT WOULD BE DIFFICULT TO DO ALONE," EXPLAINED JEFFREY ABRAMS, M.D., DIRECTOR, CLINICAL RESEARCH, DIVISION OF CANCER TREATMENT AND DIAGNOSIS, AND ASSOCIATE DIRECTOR OF THE CANCER THERAPY EVALUATION PROGRAM, NATIONAL CANCER INSTITUTE (NCI), RETIRED. "THE CHALLENGE OF OUR TIME WILL BE TO MAKE IMMUNOTHERAPIES WORK EVEN BETTER FOR INDIVIDUAL PATIENTS TO GENERATE THE RAPID PROGRESS THAT WE'D ALL LIKE TO SEE."EXPANDING THE ACCELERATING MEDICINES PARTNERSHIPTHE ACCELERATING MEDICINES PARTNERSHIP (AMP) HAS SERVED AS AN EFFECTIVE VEHICLE FOR PUBLIC-PRIVATE PARTNERSHIPS IN BIOMEDICAL RESEARCH SINCE 2014. AMP INITIALLY BROUGHT TOGETHER THE FNIH, NIH AND FDA WITH NOT-FOR-PROFIT ORGANIZATIONS AND INDUSTRY TO ACCELERATE EARLY-STAGE DRUG DEVELOPMENT IN ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND THE AUTOIMMUNE DISORDERS RHEUMATOID ARTHRITIS (RA) AND SYSTEMIC LUPUS ERYTHEMATOSUS. BY ENABLING JOINT PLANNING OF RESEARCH IN THE HIGHEST AREAS OF NEED AND SHARING RESOURCES, EXPERTISE AND DATA, AMP HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING DISEASE PATHWAYS AT THE MOLECULAR LEVEL AND IN IDENTIFYING NEW TARGETS FOR TREATMENTS. ALL OF THE DATA GENERATED FROM AMP ARE MADE BROADLY AVAILABLE TO THE RESEARCH COMMUNITY THROUGH ONLINE KNOWLEDGE PORTALS FOR USE IN DRUG DISCOVERY AND DEVELOPMENT.IN 2018, THE AMP TEAM EXPANDED WORK IN TWO KEY AREAS:1. LAUNCH OF AMP PARKINSON'S DISEASE (AMP PD): THE NUMBER OF PEOPLE LIVING WITH PARKINSON'S DISEASE IS EXPECTED TO NEARLY DOUBLE BY 2040, ACCORDING TO THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, AND THERE ARE STILL NO DISEASE-MODIFYING DRUGS (NINDS) APPROVED FOR TREATMENT. THROUGH THE NEW AMP PD PROGRAM, RESEARCHERS WILL TRANSFORM THE CURRENT MODEL FOR DEVELOPING DIAGNOSTICS AND TREATMENTS FOR PATIENTS BY IDENTIFYING AND VALIDATING BIOMARKERS THAT TRACK DISEASE PROGRESSION AND SERVE AS NEW DRUG TARGETS.2. EXTENSION OF AMP RA/LUPUS TO A 6TH YEAR: THIS PROGRAM EXTENSION WILL ENABLE RESEARCHERS TO DEPLOY EMERGING TECHNOLOGIES THAT CAN FURTHER ANALYZE TISSUE, BLOOD AND URINE SAMPLES FROM PATIENTS LIVING WITH RA OR LUPUS. THE PROGRAM WILL CREATE A MORE DETAILED UNDERSTANDING OF THE MOLECULAR NATURE OF THESE DISEASES. BY EXAMINING SAMPLES AT THE SINGLE-CELL LEVEL RESEARCHERS ARE IDENTIFYING THE GENES, PROTEINS AND CHEMICAL PATHWAYS THAT PLAY IMPORTANT ROLES IN THESE DISEASES AND UNCOVERING NEW TARGETS FOR DRUG DEVELOPMENT.
Interesting data from their 2020 990 filing
The non-profit's mission is outlined in the filing as being “See schedule o, statement of organization's primary exempt purpose statementthe foundation for the national institutes of health was established by the united states congress to support the nih in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. the foundation builds partnership for discovery and innovation to improve health. the board has an executive committee which can make decisions on behalf of the board (with some exceptions) in between board meetings.”.
When outlining its responsibilities, they were referred to as: “The foundation for the national institutes of health (fnih) creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives.”.
- The state in which the non-profit operates has been officially reported as MD.
- The filing reveals the non-profit's address in 2020 to be 11400 ROCKVILLE PIKE NO 600, NORTH BETHESDA, MD, 20852.
- As per the non-profit's form for 2020, they have 65 employees on their payroll.
- Is not a private foundation.
- Expenses are greater than $1,000,000.
- Revenue is greater than $1,000,000.
- Revenue less expenses is $21,264,384.
- The organization has 24 independent voting members.
- The organization was formed in 1996.
- The organization pays $8,639,303 in salary, compensation, and benefits to its employees.
- The organization pays $221,918 in fundraising expenses.
Additional Non-Profits in the area
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.